Price Forecast:

Bullish Case: Bio-Techne's recent partnerships and product innovations, particularly in spatial biology, are catalyzing growth, evidenced by a strong demand forecast, indicating a rebound in stock price above $75.

Bearish Case: Sluggish sales in the diagnostics segment and continued uncertainties in the biotechnology funding landscape may pressure stock performance, constraining it below $60.

Potential Outcomes:

1. Increased adoption of innovative products boosting sales (60%);

2. Ongoing funding issues hampering growth (50%);

3. Regulatory delays impacting new product launches (40%);

4. Expansion of partnerships enhancing market share (55%);

5. Recovery of sales in China (45%).

Trading Oracle: Consider a bullish vertical debit spread by purchasing the TECH 12/20/2024 $70 call and selling the $80 call. This strategy leverages positive momentum with a favorable risk/reward profile. Monitor volatility shifts and aim for a 1-2 month horizon to maximize gains, targeting a price move post-earnings release.

November 20, 2024